Ponatinib
About
Therapy type: Targeted therapy
Therapy strategy: BCR-ABL inhibition
Mappings
NCI Thesaurus: Ponatinib (ncit:C95777)
Therapeutic response
Precision oncology relationships for therapeutic response involving this therapy.| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | BCR::ABL1 | Acute Lymphoid Leukemia | Cytarabine, Methotrexate, Ponatinib, Prednisone, Vincristine | |
| Sensitivity (+) | ABL1 p.T315I, BCR::ABL1 | Acute Lymphoid Leukemia | Ponatinib | |
| Sensitivity (+) | ABL1 p.T315I | Chronic Myelogenous Leukemia | Ponatinib | |
| Sensitivity (+) | ABL1 p.T315I | Chronic Myelogenous Leukemia | Ponatinib | |
| Sensitivity (+) | BCR::ABL1 | Acute Lymphoid Leukemia | Ponatinib | |
| Sensitivity (+) | ABL1 p.T315I, BCR::ABL1 | Acute Lymphoid Leukemia | Ponatinib | |
| Sensitivity (+) | ABL1 p.T315I | Chronic Myelogenous Leukemia | Ponatinib | |
| Sensitivity (+) | BCR::ABL1 | Acute Lymphoid Leukemia | Ponatinib | |
| Sensitivity (+) | ABL1 p.T315I, BCR::ABL1 | Acute Lymphoid Leukemia | Ponatinib |